Upcoming events

Stents and scaffolds

Here you will find all the latest content on stents and scaffolds published on this website. Results are listed in chronological order.

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents and scaffolds

358 results

MASTER: Safety and efficacy of biodegradable polymer DES in management of patients with acute STEMI

From EuroPCR 2016

M. Valdes introduces the MASTER study showing us just how BMS were put to the test. Taking a close look at the treatment of patients with acute STEMI, MASTER compares DES with bioresorbable polymer with bare metal stents. And the outcomes? At 4 and 6 months, in a population representative of daily practice, the results were in favour of the DES.Learn more about the details of this study – efficacy and favourable short-term safety, late lost, target vessel failure.

BRS in long lesions - Optimising implantations results

By beginning with the question of what in fact constitutes a long lesion, M. Haude and N.E.J. West lead us through an illuminating discussion of bioresorbable scaffolds and why, with increasing experience they pose a valid alternative to the former dependence on a “full metal jacket” philosophy.What are the procedural aspects that differ with BRS that are essential in their good deployment? What are the specific pitfalls or structural concerns about these devices when used in long lesions? And what about DAPT? Learn more on where we stand today with the clinical uses of BRS…

BRS: experience, unresolved issues and the outlook for the next-generation

One of the hottest topics in stenting, bioresorbable scaffolds have captured the imagination of today’s interventionalists…but what is the status of these promising devices: their current data, challenges or future?Join M. Haude, A. Abizaid and N. E. J. West as they look at the efficacy and safety of first-generation BRS. What are their limitations and what lessons can we learn from available data and experience? Learn more as they touch on such subjects as the challenges of patient selection, lesion preparation and the use of imaging. Where are we going with BRS? Learn more here…

France ABSORB registry - In-hospital and one-month results in 2,000 patients

From EuroPCR 2016

The future of bioresorbable stents is happening now and the French ABSORB registry launched in September 2014 has been designed to measure “real-world” results of these emerging devices. MACCE? Thrombosis rates?Join R. Koning as he walks us through the results of this wide-scale and intriguing registry with a clear take home message… 

Two-year follow-up of everolimus-eluting BRS vs. metallic stent - the randomised ABSORB Japan trial

From EuroPCR 2016

Data in the world of BRS is growing and here, within the context of the ABSORB Japan trial, Y. Onuma looks at the clinical results of a comparison between two everolimus-eluting stents – one a BRS, the other metallic.What did they find at 2-years in terms of healing or lumen area? And what was their conclusion concerning the question of stability in terms of the bioresorbable scaffold? Learn more…

1 year results of first-in-man trial randomising the sirolimus eluting polylactide scaffold & everolimus eluting polylactide scaffold

From EuroPCR 2016

P. Serruys is one of oracle’s of interventional cardiology, a pioneer in the forefront of technology and advancing clinical practice. Join us as we speak with him about the exciting second generation of BRS as he introduces 1-year results of a first-in-man trial randomising two drug-eluting scaffolds: one using sirolimus, the other with everolimus ….The future is waiting, find out why by watching with us here!

LEADERS FREE: the balance of thrombosis and bleeding in patients at high-bleeding risk

From EuroPCR 2016

LEADERS FREE is a trial in the news, focussing on high-bleeding risk patients, new types of stents and shortened DAPT, P. Urban walks us through one aspect of this much talked about trial, focussing on why they chose to turn their attention to patients at high-risk for bleeding; patients who are, most likely, at high-risk as well for thrombosis. Until now these individuals, which represent 20% of the cathlab population, have been excluded from clinical trials, leading to a critical lack of data concerning their treatment.Learn why LEADERS FREE is changing that!

The effect of DAPT termination after BVS implantation at 12 months in regular clinical practice

From EuroPCR 2016

This study focuses on stopping DAPT at 12 months in patients who have received BVS. Will the effects be the same as DES? What are the best predictors for stopping DAPT? Will they be the classical indicators?Join R. J. Van Geuns as he describes this regional review of over 800 patients in everyday clinical practice as they examine DAPT termination after BVS implantation on very late scaffold thrombosis…

EuroIntervention - Bioresorbable vascular scaffold implantation in STEMI patients

From EuroPCR 2016

Bioresorbable vascular scaffolds (BRS) and their implantation in STEMI patients was the focus of two recent articles in EuroIntervention. V. Kodka and R. Diletti were invited by PCR TV to discuss their papers with T. Gori.What is the rationale for using BVS in the setting of STEMI or ACS in general? Does the architecture of BVS play a positive role in treating STEMI? How patients selected and what is the impact of new devices in complex settings? These and other topics are featured in this wide-ranging discussion on BVS, at an important stage in its evolution and use … Join us!Find out more about EuroIntervention Journal

Efficacy and safety of dual antiplatelet therapy after complex PCI

10 Jan 2017

Dejan Milasinovic


Dejan Milasinovic